Daytime Sleepiness (Credit: Canva)
Experiencing daytime sleepiness is something that is usually perceived as a minor inconvenience, but for older adults, it could be an early warning sign of Dementia. This neurodegenerative disease leads to the progressive decline of brain cells. This eventually
affects memory, cognition, and personality, making everyday tasks more difficult. As one of the fastest-growing neurological disorders across the world, dementia poses a significant health threat to ageing populations.
For this study, researchers followed 445 older adults (average age 76) over three years, aiming to determine whether poor sleep could increase the risk of mild cognitive impairment (MCI), which often leads to dementia. At the start, none of the participants had MCI, but by the end of the study, 36 individuals had developed the condition.
The researchers discovered that participants with poor sleep were more likely to develop MCI compared to those who slept well. However, when depression symptoms were taken into account, the link between poor sleep and MCI became less pronounced, suggesting that while sleep issues are a concern, mental health also plays a key role in dementia risk.
To assess sleep quality, the Pittsburgh Sleep Quality Index (PSQI) was used, evaluating factors such as sleep duration, disturbances, and daytime alertness. Among these, "daytime dysfunction"—defined as excessive sleepiness and low energy during the day—was most strongly associated with an increased risk of MCI. Those experiencing daytime dysfunction were more than three times as likely to develop MCI as those who didn’t report such symptoms.
There are many types of dementia:
Dementia is not a specific disease. According to the Centers for Disease Control and Prevention (CDC), it is an overall term that describes a decline in mental ability that interferes with daily life. People with dementia often have symptoms like trouble remembering, thinking, or making everyday decisions. These symptoms tend to get worse over time.
Alzheimer’s disease is the most common type of dementia, and it mostly affects the elderly. Each form of dementia has a different cause. Though dementia mostly affects older adults, it is not a part of normal ageing. An estimated 6.7 million older adults have Alzheimer's disease in the United States. That number is expected to double by 2060, as per data from the CDC.
In 2022, 3.8% of men and 4.2% women in US were diagnosed with dementia. The percentage of people increase with age from 1.7% for those aged 65-74 to 13.1% for those aged 85 and older. Alzheimer's accounts for 60 to 80% of all dementia cases and it is most prevalent in California, Florida, and Texas, as these states have the highest number of people.
Credit: AI
Propranolol is a beta-blocker that is used to address certain heart conditions and physical symptoms of anxiety. It has been gaining attention on social media for calming nerves before stressful life events like job interviews, presentations and other similar situations.
However, experts warn that its surging popularity may make it difficult to pay attention to the limited evidence supporting its use for anxiety.
The medication works by blocking the effects of adrenaline on beta receptors, slowing the heart rate and reducing physical symptoms like trembling, sweating and palpitations. It does not directly treat the emotional symptoms of anxiety.
In England, the NHS dispensed around 8.4 million propranolol prescription items in the 12 months leading up to June 2026, a 4.7% increase from the previous year. These figures cover all uses of the drug, not just anxiety.
Significant increases in prescriptions among younger women and teenage girls over a decade was also seen. Social media has helped promote propranolol as a quick fix for nerves, but its popularity does not reflect the strength of its clinical evidence.
Also read: Seasonal Depression & Anhedonia: How Winter Can Affect Pleasure And Motivation
Dr Daniel Gordon, private GP and managing director at DGA Health told Daily Mail that propranolol may help people whose anxiety mainly causes physical symptoms.
"In my experience, the people who find propranolol helpful are usually those whose anxiety shows up mostly in the body, with palpitations, shaking and a pounding chest," Dr Gordon said.
He also said that addressing those symptoms can treat physical symptoms, helping people feel more in control. But feeling calmer in the body is not the same as treating anxiety, and for many people talking therapies, and sometimes other medicines, prove to be helpful.
Additionally, the evidence available on Propranolol is insufficient contrary to its online popularity. A systematic review of eight small randomised trials, covering around 200 people, concluded that the evidence was insufficient to support routine use of propranolol in any anxiety disorder.
Some people do report relief of physical symptoms, but propranolol us not recommended for anxiety as there are no modern, reliable clinical trials.
Dr Gordon added, "This is exactly why proper assessment matters. Propranolol should generally not be used by people with asthma, certain heart rhythm problems such as heart block, a very slow heart rate or low blood pressure, and it can mask the warning signs of low blood sugar in people with diabetes."
Common side effects of propranolol include dizziness, tiredness, cold hands and feet, and sleep disturbances. Because propranolol can decrease heart rate and blood pressure, it may be unsuitable for people with low blood pressure. It can also be risky for people with asthma and heart conditions.
Buying prescription medication online is not inherently unsafe, but a brief questionnaire does not necessarily mean that a person's medical history and individual risks have been adequately assessed.
Gordon stressed that a medical doctor needs to review a patient's medical history before prescribing the drug as it can interact with other medications and may be unsuitable for some patients.
Propranolol may help some people manage physical symptoms in some situations, but it is not a substitute for treating clinical anxiety.
Psychological therapies, including cognitive behavioural therapy (CBT), can help people manage anxious thoughts. Medication may also be appropriate depending on the person's symptoms.
People whose anxiety affects their work, relationships or daily activities should speak to a healthcare professional rather than taking propranolol.
Credit: iStock
Police in Guinea-Bissau raided the Bandim Health Project on Monday, October 19, and seized a batch of hepatitis B vaccines intended for a controversial trial involving 14,000 newborns, according to an official statement.
The project’s Danish researchers, Peter Aaby and Christine Stabell Benn, are at the center of the dispute. The study received $1.6 million from the US Centers for Disease Control and Prevention (CDC), matched by the Pershing Square Foundation and the Bluebell Foundation, bringing total funding to $3.2 million. US Health and Human Services Secretary Robert F. Kennedy Jr. has praised the researchers’ work.
The police search took place on Monday, involving “investigative procedures aimed at clarifying the circumstances related to the said batch of vaccines”, according to the social media post, which was translated from Portuguese. The announcement noted that seizing the immunizations did not point to “irregularities in the quality, safety, or effectiveness of the vaccines”, The Guardian reported.
The proposed trial would randomly divide 14,000 newborns into two groups: one would receive the hepatitis B vaccine at birth, while the other would receive it six weeks later.
The WHO recommends hepatitis B vaccination within 24 hours of birth to prevent mother-to-child transmission.
Also read: Hepatitis B Infections Could Rise 83% If US Changes Newborn Vaccine Policy: Study
Hepatitis B is highly endemic in Guinea-Bissau, affecting more than 12% of adults. Infants infected at birth have about a 90% chance of developing chronic infection, which can lead to cirrhosis, liver failure and liver cancer.
Stig Børsen Hansen, a member of the University of Southern Denmark’s ethics committee, resigned after the committee narrowly approved the updated protocol. He warned that the trial would expose some newborns to potentially serious infections by delaying vaccination.
Rather than testing the vaccine’s established efficacy, the study aims to investigate the proposed “non-specific effects” of vaccines — potential health effects beyond protection against targeted infections.
Critics argue that delaying a recommended birth dose to investigate these hypotheses exposes newborns to avoidable risks. Former Guinea-Bissau Health Minister Magda Robalo and other critics have also raised concerns about conducting such research in a vulnerable population.
The Bandim Health Project published an approval letter from Guinea-Bissau’s national ethics committee, dated July 14. A Danish research ethics committee also approved the study earlier this month.
However, transitional government Health Minister Quinhin Nantote disputed reports that the trial would proceed, telling The Guardian: “This is not even remotely true.”
WHO spokesperson Tarik Jašarević said a study denying newborns the vaccine would be “unethical” and expose them to “serious and potentially irreversible harm.” The WHO is advising Guinea-Bissau’s Ministry of Health on introducing the vaccine and assessing the study’s potential impact.
Anthropologist Peter Aaby founded the Bandim Health Project in 1978. It is now co-led by his wife, epidemiologist Christine Stabell Benn.
Kennedy has called the pair “the deities of vaccine research” at an anti-vaccine conference and cited their research on the diphtheria-tetanus-pertussis (DTP) vaccine. A subsequent study by the researchers produced different results.
Kennedy also called Aaby a “very famous” researcher on Joe Rogan’s podcast in 2023 and cited his work when he halted US funding to Gavi, the Vaccine Alliance.
Stabell Benn served on the hepatitis B working group of the US Advisory Committee on Immunization Practices (ACIP) and presented evidence before the committee voted to end the universal hepatitis B birth-dose recommendation. A federal judge subsequently stayed the decision.
Credit: Times Network
With digital innovation, expanding healthcare access, and a growing focus on self-reliance driving transformation in India's healthcare sector, the Times Network India Health Summit & Awards 2026 is set to return for its third edition.
The event, to be held on October 28th, will bring together policymakers, healthcare leaders, clinicians, researchers, innovators, and industry stakeholders to discuss the future of India's healthcare ecosystem.
Centered on the theme, “The Blueprint for a Future-Ready Healthcare Ecosystem – Innovation. Access. Self-Reliance,” the summit will explore emerging healthcare innovations, collaborations, and policy approaches, culminating in an awards ceremony recognizing excellence across the sector.
As India is advancing in artificial intelligence (AI), digital health, biotechnology, medical technology (MedTech), and indigenous manufacturing, these areas will also be central to discussions on strengthening the country's healthcare ecosystem.
Anupriya Patel, Union Minister of State for Health and Family Welfare and Minister of State for Chemicals and Fertilizers, is expected to attend as the chief guest.
The second edition of the Times Network India Health Summit & Awards 2026 will feature:
The summit will feature six panel discussions covering key areas of healthcare innovation, access, and policy.
The summit is being held in association with Onextel Communications Media, co-powered by Novartis and supported by HealthandMe. It will conclude with a felicitation ceremony recognizing excellence across the healthcare sector.
© $2026 Times Horizon Private Limited